ORTEXORTEX News
Tracking ALKT? Get live short interest, options flow, and signals on ORTEX.Sign up free →
AL
Trader NoteALKT

ALKT heads into earnings with activists on board and analysts divided

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 3 min readdata as of 21 Oct 2026, 20:33

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Alkami Technology reports on October 28, one week away, and the setup is more complicated than the stock's recent bounce suggests.

The share price has recovered 3.6% on the week to $14.66, a partial rebound from a bruising month that saw it fall 23%. That monthly drop is the context for everything else in this note. The stock has been repriced sharply lower, analysts have cut targets aggressively, and two activists are now on the register with meaningful stakes. The question heading into next week is whether the repricing is complete or whether the earnings print resets expectations again.

The most newsworthy structural fact about ALKT right now is the activist presence. General Atlantic, with an 18.1% stake and five Schedule 13D/A filings since February 2025, is the largest single holder and is clearly engaged. JANA Partners, which first filed a 13D in April 2026, holds 6.3% and filed its most recent amendment on October 16, five days ago. Two active 13D filers accounting for roughly a quarter of the company between them is not routine. As always with 13D/G disclosures, stakes are as last disclosed around the 5% threshold, and positions can change without a further filing.

The analyst picture has moved decisively in one direction: down. In late September, JP Morgan's Ella Smith made the most dramatic move on the Street, cutting the rating from Overweight to Underweight and slashing the target from $24 to $14. That followed a target lift from $19 to $24 in August, making the reversal all the more stark. Barclays lowered its target from $21 to $15 on October 12, maintaining Equal-Weight. Against that, Citizens has reiterated Market Outperform with a $24 target, and Needham holds a Buy. The consensus mean target of $19.86 sits roughly 35% above the current price, but the direction of travel from the two largest recent movers is clearly bearish. The bull case, per the company's own disclosures, rests on DSSP adoption now at 48 of 307 clients, net dollar retention above 115%, and long-duration contracts averaging about 70 months. The bear case is organic growth decelerating from 29% headline to 17% organic in Q1 2026, guidance implying further moderation, and a field of well-resourced competitors including Q2, Jack Henry and Fiserv.

Positioning in the lending market is relaxed, and that's noteworthy given the price weakness. Short interest at 6.1% of the free float is moderate and has actually eased slightly over the past week, down 1.7%, though it has drifted roughly 5% higher over the past month. Borrowing costs are low at 0.53% and have come down 7% on the week. Availability is ample at 210%, meaning roughly two shares are available to borrow for every one already lent out. Nothing in the lending market points to a crowded short or squeeze pressure. Options sentiment corroborates this: the put/call ratio of 0.36 is running slightly below its 20-day average of 0.39, which is mildly call-skewed rather than defensive. Neither positioning signal looks alarmed ahead of earnings.

One data point worth flagging separately is retail attention. The ORTEX alternative data layer registers a Wikipedia views z-score of 5.25 as of October 19, an unusually high reading measuring retail attention against Alkami's own prior 90-day history. This is an attention signal, not a revenue indicator, but it suggests the stock is drawing more retail interest than usual, likely a function of the sharp drawdown and the approaching earnings date.

The earnings history offers limited precedent: the single prior print on record showed a 2% fall on the day followed by a 3.5% recovery over the following week. Peers have moved sharply more than ALKT in recent weeks, with QTWO and BILL each gaining more than 11% on the week and VERX up nearly 13%, while ALKT added only 3.6%. The relative underperformance keeps the stock lagging the fintech software group into its own print.

The week ahead will be less about whether Alkami is growing and more about whether October 28 guidance language gives JANA and General Atlantic something to work with, or hands the bears another reason to trim targets.

Stocks in this article

See the live data behind this article on ORTEX.

Open ALKT on ORTEX →

How this article was generated

Generated
21 Oct 2026, 20:43
Data as of
21 Oct 2026, 20:33
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.